Charles River Laboratories has made changes within its Research Models and Services (RMS) and Preclinical Services (PCS) and Sales organizations. Real H. Renaud, corporate executive vice president and president, Global RMS, announced he will retire by the end of 2010. As part of the transition of Mr. Renaud’s responsibilities, Davide Molho, D.V.M. has been promoted to corporate senior vice president, North American and European RMS.

James C. Foster, chairman, president and chief executive officer, said, “Real Renaud has had a stellar career at Charles River, beginning 45 years ago and rising through the ranks to head our global RMS business. Under his leadership, we have become the premier provider of research models and scientific support services to the drug development industry, recognized worldwide for our quality, biosecurity and scientific expertise. Real has developed a world-class management team, including his successor, Davide Molho, which positions us extremely well to maintain our market leadership.”

Dr. Molho joined Charles River Italy in 1999, and was promoted to director of operations for RMS Italy in 2002. In 2005, his role was expanded to include all French RMS operations and in 2007, he became corporate vice president, European RMS.

Through the restructure of the PCS business, the company created a dual-accountability structure with both global functional teams and site-level management, in an effort to increase harmonization and integration of all services across the PCS organization.

Under the new global operations structure, Brian Bathgate, Ph.D., corporate senior vice president, will assume responsibility for Global Laboratory Sciences in addition to his current responsibility for Global Biopharmaceutical Services. Dr. Bathgate will maintain oversight of PCS, Europe. Christopher J. Perkin, D.A.B.T., corporate senior vice president, will oversee site operations in North America and China. He will have responsibility for harmonizing technical operations and site infrastructure. Stephen K. Durham, D.V.M., Ph.D., D.A.C.V.P., corporate vice president, will assume responsibility for global toxicology and pathology. Dr. Durham will set global standards for and ensure effective delivery of these services across all PCS sites. Joseph C. Siglin, Ph.D., D.A.B.T., divisional vice president, will continue to focus on implementation of the company’s Lean Six Sigma program and other global process improvement initiatives.

Charles River is also realigning its sales organization, switching from a sales approach focused on its portfolio of products and services, to one focused on value-based solutions by customer segment. The company is establishing a three-part sales organization for global biopharmaceutical companies, small and mid-size pharmaceutical and biotechnology companies, and the academic and government sector.

Dr. Christophe Berthoux, corporate executive vice president, Global Sales and Marketing, and chief commercial officer, said, “This is the next step in the evolution of our Sales organization from locally to globally focused. Consistent with the PCS restructuring, we believe the realigned sales force will more effectively address our clients’ needs, and be able to access resources throughout the organization to support each client’s specific requirements.”